These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. Hao S; Song H; Zhang W; Seldomridge A; Jung J; Giles AJ; Hutchinson MK; Cao X; Colwell N; Lita A; Larion M; Maric D; Abu-Asab M; Quezado M; Kramp T; Camphausen K; Zhuang Z; Gilbert MR; Park DM Neuro Oncol; 2018 May; 20(6):799-809. PubMed ID: 29294092 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus. Liu L; Wang H; Cui J; Zhang Q; Zhang W; Xu W; Lu H; Liu S; Shen S; Fang F; Li L; Yang W; Zhuang Z; Li J Cell Physiol Biochem; 2018; 50(1):317-331. PubMed ID: 30282066 [TBL] [Abstract][Full Text] [Related]
7. PRMT5 as a druggable target for glioblastoma therapy. Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation. Gao S; Shan L; Zhang M; Wang Y; Zhan X; Yin Y; Jiang Z; Tao X; Li X; Ye M; Liu Y Cell Oncol (Dordr); 2022 Dec; 45(6):1203-1215. PubMed ID: 36136269 [TBL] [Abstract][Full Text] [Related]
9. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Ho WS; Feldman MJ; Maric D; Amable L; Hall MD; Feldman GM; Ray-Chaudhury A; Lizak MJ; Vera JC; Robison RA; Zhuang Z; Heiss JD Oncotarget; 2016 Mar; 7(11):12447-63. PubMed ID: 26799670 [TBL] [Abstract][Full Text] [Related]
10. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. Chang KE; Wei BR; Madigan JP; Hall MD; Simpson RM; Zhuang Z; Gottesman MM Mol Cancer Ther; 2015 Jan; 14(1):90-100. PubMed ID: 25376608 [TBL] [Abstract][Full Text] [Related]
11. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Wei D; Parsels LA; Karnak D; Davis MA; Parsels JD; Marsh AC; Zhao L; Maybaum J; Lawrence TS; Sun Y; Morgan MA Clin Cancer Res; 2013 Aug; 19(16):4422-32. PubMed ID: 23780887 [TBL] [Abstract][Full Text] [Related]
13. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912 [TBL] [Abstract][Full Text] [Related]
14. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002 [TBL] [Abstract][Full Text] [Related]
15. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354 [TBL] [Abstract][Full Text] [Related]
16. LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Hong CS; Ho W; Zhang C; Yang C; Elder JB; Zhuang Z Cancer Biol Ther; 2015; 16(6):821-33. PubMed ID: 25897893 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment. Zhang C; Hong CS; Hu X; Yang C; Wang H; Zhu D; Moon S; Dmitriev P; Lu J; Chiang J; Zhuang Z; Zhou Y Cell Cycle; 2015; 14(13):2100-8. PubMed ID: 25942376 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma. Maggio D; Ho WS; Breese R; Walbridge S; Wang H; Cui J; Heiss JD; Gilbert MR; Kovach JS; Lu RO; Zhuang Z J Neurooncol; 2020 Jun; 148(2):231-244. PubMed ID: 32342332 [TBL] [Abstract][Full Text] [Related]
19. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mirzapoiazova T; Xiao G; Mambetsariev B; Nasser MW; Miaou E; Singhal SS; Srivastava S; Mambetsariev I; Nelson MS; Nam A; Behal A; Arvanitis LD; Atri P; Muschen M; Tissot FLH; Miser J; Kovach JS; Sattler M; Batra SK; Kulkarni P; Salgia R Mol Cancer Ther; 2021 Oct; 20(10):1820-1835. PubMed ID: 34253596 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair. Lv P; Wang Y; Ma J; Wang Z; Li JL; Hong CS; Zhuang Z; Zeng YX Oncotarget; 2014 Sep; 5(17):7512-24. PubMed ID: 25245035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]